Amanda Huff

Our lab is looking for a laboratory technician to work on a next generation cancer vaccine. Come join our great group! Link to apply: jobs.jhu.edu/job-invite/108… @NeehaZaidi @DrLizJaffee @AmandaHuffPhD

A large, publicly available dataset integrating RNA, whole-exome, T cell receptor and 16S rRNA sequencing from patients with #ColonCancer enables the discovery of a #PrognosticScore consisting of tumor, immune and microbial features. #Microbiome #Tcell nature.com/articles/s4159…

Breaking News: A pancreatic cancer vaccine provoked an immune response in half of the patients treated in a small trial, a finding that experts described as very promising. nyti.ms/3BhqG7E

Excited to share our @NatureNV on a promising personalized neoantigen vaccine for pancreatic cancer!

A #DeepLearning algorithm using electronic health records from two large cohorts of patients predicts the risk of #PancreaticCancer from pre-cancer disease trajectories up to 3 years in advance, w/ promising performance. nature.com/articles/s4159… @sandercbio @TheBrunakLab

Excited to share STAPLER, a language model to predict TCR – pMHC reactivity that outperforms prior models. And for ML aficionados: Description of a new data leakage problem inherent to a common negative data generation strategy. biorxiv.org/content/10.110… 🧵👇

Rudensky and colleagues find that Treg depletion in a PD-1 resistant cancer model vastly alters the TME and Treg dependent programs were identified, such as the VEGF pathway. Treg depletion and VEGF blockade improved tumor control rdcu.be/dbc67 nature.com/articles/s4159…

Learning the metabolic language of cancer go.nature.com/41Ja9EK

The @Immunologia1 lab links the immune-suppressing capabilities of #PancreaticTumors to #NeutrophilExtracellularTraps and their cleavage of the ARG1 enzyme—and show an anti-ARG1 antibody potentiates #immunotherapy and extends survival in mice. @UniVerona scim.ag/1VZ

Neoadjuvant #nivolumab, #ipilimumab and chemotherapy showed promising efficacy for resectable #NSCLC, with higher tumor immune cell infiltration and tertiary lymphoid structures post-treatment compared to nivolumab plus chemotherapy @MDAndersonNews nature.com/articles/s4159…

A #machinelearning model that utilizes longitudinal #ctDNA metrics robustly predicts survival in two phase 3 trials of patients with metastatic #NSCLC, which may improve therapy selection and risk stratification. @genentech nature.com/articles/s4159…

Exciting paper published in @NatureComms from our lab @RVilePhD @MayoClinic check it out! rdcu.be/b1mEb